Cerebral Infarction
Recent clinical, regulatory, research and industry developments relating to this disease.
Loss of SARM1 ameliorates secondary thalamic neurodegeneration after cerebral infarction.
Neuronal injuries in cerebral infarction and ischemic stroke: From mechanisms to treatment (Review).
Neural correlates of motor recovery after stroke: a longitudinal fMRI study.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 3 clinical trials expected to report results, the earliest in Q1 2028.
- Q1 2028The Effect and Safety of Therapy Adding Cilostazol in Acute Ischemic Stroke Due to Large Artery Atherosclerosis: CHANGE Trial
- Q4 2028Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation
- Q1 2029Efficacy and Safety of Tirofiban Therapy in Acute Ischemic Stroke Patients Beyond the Time Window Guided by High-Resolution Magnetic Resonance Imaging
Clinical MilestonesViewHide
- 2026-06-25Efficacy and Safety of Tirofiban Therapy in Acute Ischemic Stroke Patients Beyond the Time Window Guided by High-Resolution Magnetic Resonance ImagingResults expected Q1 2029
- 2026-06-05Stroke Prevention In Ischemic Stroke With Covert Atrial FibrillationResults expected Q4 2028
- 2026-03-27The Effect and Safety of Therapy Adding Cilostazol in Acute Ischemic Stroke Due to Large Artery Atherosclerosis: CHANGE TrialResults expected Q1 2028
- 2026-06-25ClinicalEfficacy and Safety of Tirofiban Therapy in Acute Ischemic Stroke Patients Beyond the Time Window Guided by High-Resolution Magnetic Resonance ImagingResults expected Q1 2029
- 2026-06-05ClinicalStroke Prevention In Ischemic Stroke With Covert Atrial FibrillationResults expected Q4 2028
- 2026-03-27ClinicalThe Effect and Safety of Therapy Adding Cilostazol in Acute Ischemic Stroke Due to Large Artery Atherosclerosis: CHANGE TrialResults expected Q1 2028
- 2026-03-01ClinicalSafety and Efficacy of Treatment With Early Antiplatelet Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT): A Multicenter, Randomized, Placebo-controlled, Clinical TrialPrimary completion
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes7
- Alzheimer Disease2
- Brain Ischemia2
- Heart Arrest1
- Ischemic Stroke1
- Motor Skills1
- Proteostasis Deficiencies1
- Stroke1
Leading journals4
- International journal of molecular sciences2
- Brain : a journal of neurology1
- International journal of molecular medicine1
- Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism1
Leading researchers8
- Chen X2
- Pluta R2
- Brown MM1
- Czuczwar SJ1
- Fan Y1
- Frackowiak RS1
- Li G1
- Li J1
Affiliations (unnormalised)5
- Medical University of Lublin2
- Guangdong Provincial Key Laboratory of Laboratory Animals1
- Institute of Neurology1
- The First Affiliated Hospital1
- University of California Berkeley1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Cerebral infarction is an area of necrosis in the cerebrum caused by insufficient arterial or venous blood flow. It is commonly discussed as an ischemic stroke event and may be classified by hemisphere, lobe, arterial territory, or etiology such as embolic infarction.
It is caused by transient or permanent occlusion of cerebral vessels leading to reduced blood flow to brain tissue. The grounding also identifies embolic infarction as one etiologic category.
Insufficient cerebral perfusion produces ischemic injury, resulting in brain infarcts, tissue death, and focal neuronal damage. The severity and size of the infarct depend on factors such as the duration and severity of ischemia, systemic blood pressure, venous circulation, and infarct location. Postischemic injury involves disturbed cellular homeostasis, including altered autophagy in neuronal, glial, and vascular cells.
The grounding supports systemic blood pressure and infarct location as factors associated with infarct severity, rather than established risk factors for developing the disease. It also indicates that the time period since occurrence and the severity of ischemia influence neurological severity.
AI-generated summary grounded in MeSH and 2 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.